Noem Visits Portland ICE Facility Amid Troop Dispute | JQJO

The Department of Justice has opened an investigation into former Trump campaign adviser Corey Lewandowski after receiving a criminal referral from the Department of Homeland Security Office of...

Pop star Charli XCX will appear in a cameo in Martin Scorsese’s next psychological thriller, *What Happens at Night*, which stars Leonardo DiCaprio and Jennifer Lawrence as a married couple traveling to a European small town to adopt a baby. The film, a co‑production between Apple and StudioCanal, has no release date announced yet. Scorsese and XCX previously collaborated on the *Music, Fashion, Film* project, which featured John Cale, Marc Jacobs and the director himself. XCX has also appeared in several films last year, including Gregg Araki’s *I Want Your Sex*, Pete Ohs’ *Erupja*, and Aidan Zamiri’s mockumentary *The Moment*. She also wrote the soundtrack for Emerald Fennell’s *Wuthering Heights* and co‑wrote music for A24’s *Mother Mary*.

Hall of Fame running back Marshall Faulk, 53, revealed on a podcast Wednesday that he has been diagnosed with Parkinson's disease. He said he has been dealing with the disorder for a year and a half and caught it early, allowing for effective treatment. Faulk emphasized the importance of early diagnosis and noted that his medication has helped him manage symptoms such as hand rigidity and tremors. He remains active as head coach at Southern University and continues to live his life with the condition.

Typhoon Champi is barreling toward Taiwan, China and Japan, bringing heavy rain and wind. Taiwanese authorities issued urgent safety warnings on Thursday, urging the public to avoid high‑risk zones. The storm’s 320‑kilometre radius will cover most of Taiwan today, with peak impact expected through the night before it pulls away toward southern Japan late Saturday. Severe weather warnings are in place across Taiwan, with mountainous regions facing up to 900 millimetres of rainfall and wind gusts reaching level twelve on the Beaufort scale.

YouTube has begun testing a change that removes the Subscriptions tab from the bottom navigation bar on its Android and iOS apps. The tab is now positioned in the top bar on the Home screen, appearing as the second item after Home. This shift follows a decade of the tab’s placement in the bottom bar, dating back to 2017. Alongside the move, YouTube is introducing custom feeds for Live, Music, and Movies & TV, and is redesigning the top bar to feature dedicated feeds. The changes are part of a broader effort to streamline the Home experience and are currently in testing on mobile and desktop for U.S. users.

Texas coach Steve Sarkisian said Arch Manning is "edgy" after back‑to‑back losses to unranked opponents. The Longhorns, ranked No. one, fell 27‑24 to Oklahoma in Week six and again 27‑24 to Florida in Week seven. Both defeats came after Manning committed pivotal fourth‑quarter turnovers. Sarkisian noted the quarterback’s edge and expressed confidence that he will fight back. Texas faces No. seven Ole Miss next, with the outcome affecting playoff hopes.

Experts say that, one day after governments warned that severe PHP flaws could force websites offline, there have been few, if any, reports of widespread damage. Across all telemetry, Sophos’ Don Smith noted only a couple of real exploitation attempts. Industry leaders—including CrowdStrike, ESET, Google Threat Intelligence Group, Huntress, Palo Alto Networks, Recorded Future, SecureWorks, Sophos and Trail of Bits—reported to NBC News that, as of Thursday evening, no successful attacks had been observed. The vulnerabilities, affecting an estimated 69% of all websites, were quietly patched after a global effort, and many sites went dark until updates were applied. Cybersecurity experts warn the threat will remain for weeks, if not longer, but early signs suggest the flaws are harder to exploit than initially thought.

A late‑stage trial of Moderna and Merck’s melanoma vaccine, intismeran autogene, combined with Merck’s Keytruda, reduced the relative risk of disease recurrence or death by 42% compared with Keytruda alone after a median follow‑up of 24.6 months. The result, disclosed ahead of the European Society for Medical Oncology meeting, met the study’s primary endpoint and was described by analysts as a landmark moment. Shares of both companies fell immediately, with Moderna’s stock dropping nearly 25% and Merck’s falling about 1%. Analysts noted a “sell‑the‑news” reaction to the announcement. The 42% reduction is slightly below the 44% observed in a smaller Phase 2 trial, but still represents a significant clinical benefit.